Cleveland BioLabs Announces Appointment of Biotechnology

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cleveland BioLabs Announces Appointment of Biotechnology Industry Veteran, Langdon Miller, MD, as President and Chief Medical Officer

BUFFALO, NY--(Marketwired - May 5, 2015) - Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today announced the appointment of Langdon L. Miller, M.D., as President and Chief Medical Officer, effective immediately. 

Dr. Miller has served as a strategic medical advisor to Cleveland BioLabs since February 2014. He has more than 20 years of experience in the design and conduct of translational and clinical drug development programs in oncology (both in hematological and solid tumors) and orphan diseases. Dr. Miller has worked in all phases of drug development, from first-in-human studies through pivotal registration-directed trials to medical affairs programs and has filed multiple Investigational New Drug applications, Clinical Trial Applications, New Drug Applications and orphan drug applications. He played major roles in the development of filgrastim and sargramostim, in the regulatory approvals of irinotecan, exemestane, epirubicin, dexrazoxane, sunitinib, and idelalisib in several cancers, and in validating new endpoints for Duchenne muscular dystrophy and cystic fibrosis. Dr. Miller has extensive experience in the generation, analysis, presentation, and justification of drug development programs before regulatory authorities, advisory committees, investigators, investors, and business development partners. He has authored over 100 regulatory documents and publications. Prior to establishing his consultancy in 2013, Dr. Miller held leadership positions in government and in large and small biopharmaceutical companies, including the National Cancer Institute, Pharmacia Corporation, PTC Therapeutics, Calistoga Pharmaceuticals, and Gilead Sciences. He holds a Doctorate of Medicine from Northwestern University and completed his residency in internal medicine at the University of Minnesota and an oncology fellowship at Stanford University. 

Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, "We are thrilled to welcome Langdon as a member of the CBLI executive team. His guidance over the past year has contributed to significant progress with our entolimod biodefense indication and multiple clinical programs. We are grateful for his commitment at this critical time in our development."

Dr. Miller noted, "My involvement with CBLI has continued to expand over the past several months. I believe that the company is in a unique position to advance novel treatments in the areas of acute radiation syndrome and immunotherapy. I look forward to providing leadership in facilitating the development strategy for the entire investigational pipeline." 

About Cleveland BioLabs, Inc. Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's most advanced product candidate is entolimod, which is being developed for a biodefense indication and as a potential cancer treatment. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and through two joint ventures, Panacela Labs, Inc. and Incuron, LLC. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com .

This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words and phrases such as "believe," "plan," "potential," "will," "look forward" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the conduct and results of our various clinical trials; the efficacy of our therapeutic products; our ability to successfully complete planned clinical studies; and our ability to obtain regulatory approval for our therapeutic products. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. 

These factors include, among others, the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's collaborative relationships and the financial risks related thereto; the Company's ability to comply with its obligations under license agreements; subsequent changes in the agreement with the Russian Ministry of Industry and Trade; the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; and the Company's need for substantial additional financing to meet its business objectives. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.

Contacts: Cleveland BioLabs, Inc. Rachel Levine Vice President, Investor Relations T: 917-375-2935 E: rlevine@cbiolabs.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 27

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Kyndryl's Gartner Sweep Raises the Execution Bar Again

Updated Category News Views 95

A workplace help-desk ticket may sound dull as drywall, but at a giant enterprise it can become a very expensive little failure. That is why Kyndryl's latest Gartner recognition deserves more than the usual corporate backslapping. The company was named a Leader in Gartner's 2026 Magic Quadrant for Outsourced Digital Workplace Services for a third consecutive year, and...

Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 196

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 118

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Emaar's Huspy Deal Brings Financing Into Home Sales

Updated Category News Views 51

Mortgage paperwork is nobody’s idea of luxury, yet it can wreck a property sale faster than a bad floor plan. Emaar Properties has partnered with Dubai-based Huspy to give its customers access to mortgage advice and financing comparisons from more than 20 UAE banks. It is not a flashy tower launch or a headline-grabbing land purchase. Frankly, that is why investors...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 81

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 212

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 52

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 245

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 56

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading

Top 5 Most Recently Viewed Articles

Science Applications Intl's Earnings Preview: Key Insights Ahead

Updated Category News Views 170

Understanding Science Applications Intl's Earnings Preview Science Applications Intl (NYSE: SAIC) is gearing up for its quarterly earnings announcement. Investors are eager to see how the company performs and whether it meets analysts' expectations. What to Anticipate Analysts project Science Applications Intl will report an earnings per share (EPS) of $2.11, which could...

Continue Reading
Innovative Aerogels Paving the Path for Water Harvesting Solutions

Updated Category News Views 285

Introduction to Atmospheric Water Harvesting The world faces an alarming freshwater crisis, with projections indicating that vast segments of the population are at risk of water scarcity. In response, researchers have innovatively turned to atmospheric water harvesting, particularly highlighting the advancements made by the National University of Singapore (NUS). They...

Continue Reading
Class Action Lawsuit Alert for Tronox Holdings Plc Investors

Updated Category News Views 131

Insights into the Tronox Holdings Class Action Lawsuit Investors in Tronox Holdings Plc (NYSE: TROX) should be aware of a class action lawsuit initiated against the company. This legal action centers around allegations of potential securities fraud and improper business practices by Tronox and some of its leadership. The firm Pomerantz LLP, known for its expertise in...

Continue Reading
Rapport Therapeutics Set to Showcase Innovations in Healthcare

Updated Category News Views 128

Rapport Therapeutics to Attend Major Investor Conferences BOSTON and SAN DIEGO — Rapport Therapeutics, Inc. (Nasdaq: RAPP), a biotechnology firm at the forefront of developing small molecule precision medicines targeting neurological and psychiatric disorders, has expressed its excitement about participating in two notable investor conferences soon. Details of Upcoming...

Continue Reading
Northwestern Mutual Achieves Unmatched Financial Strength Ratings

Updated Category News Views 353

Northwestern Mutual Achieves Elite Financial Ratings for 35 Years For an impressive 35 years, Northwestern Mutual has consistently earned top financial strength ratings from the nation's leading rating agencies. This recognition underscores the company’s commitment to maintaining a robust financial foundation, which plays a crucial role in their ability to serve clients...

Continue Reading